EssilorLuxottica Has Lost Nearly a Third of Its Market Value. Here's What It Means for Your Practice.

The Numbers Don't Lie

EssilorLuxottica's stock has lost close to €50 billion in market value over the past twelve months. Nearly a third of the company's worth. Gone.

The share price peaked above €323 in the past year. It recently traded below €195. The market capitalisation — once firmly above €140 billion — has fallen below €100 billion.

That is not a blip. That is a structural reckoning.

And yet almost nobody in the UK independent sector is talking about what it means for them.

They should be.

Why Investors Are Spooked

The immediate trigger is smart glasses. Specifically, the fear that technology companies — Apple, Google, Samsung, Alibaba — are not just building rival products. They are building entirely new supply chains that could bypass established eyewear brands altogether.

Bernstein, one of the brokerages that covers EssilorLuxottica, published a research note in February 2026 describing the emergence of smart glasses as a "fundamental threat" to EssilorLuxottica's business model. The brokerage maintained a Market-Perform rating and cut its price target to €250, arguing that competition from tech companies is compressing the group's valuation as Apple's potential launch of smart glasses draws closer.

The logic is uncomfortable but clear. EssilorLuxottica's business is built on two pillars: owning or licensing the world's most desirable eyewear brands, and controlling the retail networks that sell them. If Apple enters wearable eyewear at scale — and builds its own supply chain to do it — neither pillar is as secure as it looked eighteen months ago.

Even if smart glasses never become the next smartphone, Bernstein argues that the structural impact on traditional eyewear markets could be permanent. New suppliers. New competitors. Disruption across the entire value chain. That argument is now being priced into the stock.

The Operational Problems Underneath

The smart glasses narrative is the headline. The operational story beneath it is equally significant for anyone in the trade.

Following EssilorLuxottica's full-year 2025 results — a record year on paper, with revenues up 11.2% to €28.5 billion and net income rising 7.2% to €3.16 billion — Bernstein flagged something that should concern every practice owner watching how the group's distribution strategy evolves.

Margin erosion is happening faster than analysts expected. The push into wholesale channels is driving it. And with a global retail estate of approximately 18,000 stores — Sunglass Hut, LensCrafters, Salmoiraghi & Viganò, FieldmannGroup and others — EssilorLuxottica faces a growing risk of cannibalising its own network as it chases wholesale volume.

That tension between wholesale growth and retail protection is not an abstract corporate problem. It directly shapes the terms on which independent practices access EssilorLuxottica's brands, the promotional support available, and the competitive dynamics on your high street.

The Acquisition Machine Keeps Running

The stock decline has not stopped EssilorLuxottica from spending.

In April 2026, the group completed the acquisition of a significant stake in Top Charoen, Thailand's largest optical retail chain. Top Charoen operates more than 2,000 stores across Thailand under multiple banners — including Top Charoen, Luxoptic, Eye Class, Big C Optical and Robinson Optical — and employs more than 6,500 people. The chain was founded in 1947 and has been a presence in Thai eye care for nearly eight decades.

Francesco Milleri, EssilorLuxottica's chairman and chief executive, described the partnership as strengthening the group's position in one of Asia's most significant optical markets and advancing what he called "the emerging wearable category."

That phrase — the emerging wearable category — is doing a lot of work. It signals how EssilorLuxottica is repositioning itself as the smart glasses threat intensifies. The Ray-Ban Meta collaboration is already a proof of concept. The Top Charoen acquisition extends the distribution infrastructure that any wearable strategy will need in Southeast Asia.

Whether that repositioning is enough to satisfy investors is the question the stock market is currently answering. Loudly.

The Broader Slowdown Nobody Is Admitting

EssilorLuxottica's problems are real. They are also happening within a wider eyewear sector under significant pressure.

Across multiple markets, sell-through in independent luxury eyewear has slowed sharply in early 2026, by an estimated 25-30% in some segments. Launch calendars are being delayed. Full-collection debuts are being replaced by safer releases: new lens colours, updated acetates, and marginal material changes rather than genuine innovation.

Retailers are protecting liquidity. Boutique owners sitting on existing inventory are asking the same practical question: why open new orders before current stock moves?

Luxury eyewear prices have climbed aggressively over the past decade. Revenue figures at many businesses still look stable — but increasingly because each frame costs more, not because more frames are selling. Unit volumes are declining. Average selling prices are rising. Price inflation is compensating for slower movement. That equation has a ceiling, and the market is beginning to test it.

What This Means for Your Practice

Here is what independents need to take from all of this.

EssilorLuxottica owns Ray-Ban. It owns Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette and Costa. It holds licensed production agreements with a significant portion of the luxury brands on your dispensing floor. Its wholesale and retail strategy shapes what your patients can find in the corporate multiples on every high street in the UK.

When a company that is central to your supply ecosystem loses a third of its market value — driven partly by investor fear that its entire brand-distribution model could be disrupted by tech — that is not a City story. That is a practice story.

Three things to watch.

First: pricing. A group managing margin erosion and under investor pressure will squeeze the supply chain. Wholesale terms, minimum orders and promotional structures do not improve in that environment.

Second: distribution decisions. EssilorLuxottica's wholesale push — the very thing Bernstein flagged as margin-diluting — means the group's brands are becoming easier for anyone to stock. That erodes the distinctiveness of carrying Ray-Ban in an independent setting. If the brand is everywhere, your stockist status means less.

Third: the tech disruption is real, regardless of what happens to EssilorLuxottica specifically. Apple, Google and Samsung are building for a future where the device on your face is a screen as much as a lens. That is a clinical and dispensing challenge as much as it is a fashion one. Patients will come in asking questions about smart eyewear within the next three years. If the independent sector is not ready with an informed, confident position, the corporate chains and tech retailers will define that conversation instead.

The independent advantage has always been knowledge, curation and trust. None of that disappears because EssilorLuxottica's stock is falling. But the landscape it operates in is shifting faster than it has in a generation.

Now is exactly the time to be thinking strategically about where your practice stands — and who you want to be when the dust settles.

If you are an existing independent owner and want support in thinking through your practice strategy in this environment, Grow Independent is the place to start.